Atara Biotherapeutics Inc (NAS:ATRA)
$ 10.28 -1.35 (-11.61%) Market Cap: 58.33 Mil Enterprise Value: 83.40 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 40/100

Atara Biotherapeutics, Inc. - Special Call Transcript

Sep 11, 2020 / 12:30PM GMT
Release Date Price: $374 (+5.06%)
Operator

Good morning, ladies and gentlemen, and welcome to the Atara Biotherapeutics ATA188 Data Conference Call. My name is Liz, and I will be your operator for today's call. I'd now like to turn the conference over to your host, Eric Hyllengren, Vice President of Investor Relations and Finance. You may now begin.

Eric Hyllengren
Atara Biotherapeutics, Inc. - Head of IR & Finance

Thank you, Liz. Good morning, everyone, and welcome to the Atara ATA188 data conference call. Earlier this morning, we issued a press release reporting exciting data from our ongoing Phase Ia clinical trial of ATA188 presented at ECTRIMS in an e-poster this morning. This press release and the slides we will be presenting during this call are available in the investors and media section of atarabio.com. I'm joined today on the call by Dr. Pascal Touchon, President and Chief Executive Officer; Dr. Jakob Dupont, Executive Vice President and Global Head of Research and Development; Dr. AJ Joshi, Chief Medical Officer; and Utpal Koppikar, Chief Financial Officer.

I'd like to remind

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot